Relationship between icotinib hydrochloride exposure and clinical outcome in Chinese patients with advanced non-small cell lung cancer

Clinical pharmacokinetics of Icotinib, an anti-cancer drug: evaluation of dose proportionality, food effect, and tolerability in healthy subjects

(2014) Dongyang Liu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Icotinib Is an Active Treatment of Non-Small-Cell Lung Cancer: A Retrospective Study

(2014) Xiaofeng Chen et al.   PLoS One

Icotinib, a potent and specific EGFR tyrosine kinase inhibitor, inhibits growth of squamous cell carcinoma cell line A431 through negatively regulating AKT signaling

(2013) Zhenzhen Gao et al.   BIOMEDICINE & PHARMACOTHERAPY

Icotinib: kick-starting the Chinese anticancer drug industry

(2013) D Ross Camidge   LANCET ONCOLOGY

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

(2013) Yuankai Shi et al.   LANCET ONCOLOGY

Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC)

(2013) Marcello Tiseo et al.   LUNG CANCER

Dramatic response to high-dose icotinib in a lung adenocarcinoma patient after erlotinib failure

(2013) Yin Guan et al.   LUNG CANCER

Effect of the CYP2C19 genotype on the pharmacokinetics of icotinib in healthy male volunteers

(2012) Can-Jun Ruan et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acquired Resistance to Erlotinib in EGFR-Mutant Lung Cancer

(2012) Jasmine Foo et al.   Journal of Thoracic Oncology

Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies

(2011) Fenlai Tan et al.   LUNG CANCER

Pharmacokinetics of Gefitinib Predicts Antitumor Activity for Advanced Non-small Cell Lung Cancer

(2010) Yoichi Nakamura et al.   Journal of Thoracic Oncology

Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors

(2010) Qiong Zhao et al.   LUNG CANCER

The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib

(2010) Yuan-Yuan Zhao et al.   MEDICAL ONCOLOGY

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity

(2008) Charles M. Rudin et al.   JOURNAL OF CLINICAL ONCOLOGY

Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption

(2007) Joseph M. Custodio et al.   ADVANCED DRUG DELIVERY REVIEWS